Watch-outs to know: The FDA has flagged serious side effects of CJC-1295, such as increased heart rate and a full-body vasodilatory reaction, meaning your blood vessels widen, which could present other concerns

Following injection, the peptides demonstrate: Subcutaneous absorption with median time to maximum concentration (tmax) of 12-24 hours for GLP1 and 24-72 hours for cagrilintide High albumin binding for both peptides (approximately 99% for GLP1), providing protection from enzymatic degradation No pharmacokinetic interaction with co-administration not affecting exposure or elimination of either peptide Steady-state achievement occurring after 4-5 weeks of once-weekly dosing for both components Predictable dose-proportional exposure with area under the curve increasing proportionally with dose Phase 1b studies confirmed that cagrilintide doses from 0.16 to 4.5 mg produced area under the curve values ranging from 926 to 24,271 nmol times h/L, while GLP1 2.4 mg consistently produced values of 12,757 to 15,305 nmol times h/L regardless of cagrilintide co-administration dose
Massage the face with the cream for 30 seconds focusing more on dark areas or spots
This is about the same as tirzepatide's effect, but it's done through different receptor pathways
Pain-wise: most patients describe it as a brief pinch